EU Committee Nod For Lilly's Ixekizumab In Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Product, to be branded as Taltz, looks set to be approved for moderate to severe plaque psoriasis after review by Europe's CHMP, with a US decision date coming up shortly for the Cosentyx competitor.
You may also be interested in...
Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.
ICER's Drug Review Agenda Includes Lung Cancer, MS, Psoriasis Products
Technology assessments planned for 2016 focus on drugs expected to be approved in the next six months.
Formulary Focus: Cosentyx Navigating Tightly Managed Psoriasis Market
Payers’ prior authorization and step therapy requirements may delay broad access to Novartis’ Cosentyx until after competition arrives in 2016 from Lilly’s IL-17 inhibitor and possibly from a biosimilar to Humira.